These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 37063837)
1. LRPPRC facilitates tumor progression and immune evasion through upregulation of m Wang H; Tang A; Cui Y; Gong H; Li H Front Immunol; 2023; 14():1144774. PubMed ID: 37063837 [TBL] [Abstract][Full Text] [Related]
2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303 [TBL] [Abstract][Full Text] [Related]
3. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression. Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468 [TBL] [Abstract][Full Text] [Related]
4. N Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901 [TBL] [Abstract][Full Text] [Related]
5. FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma. Wang Q; Tan W; Zhang Z; Chen Q; Xie Z; Yang L; Tang C; Zhuang H; Wang B; Jiang J; Ma X; Wang W; Hua Y; Shang C; Chen Y Apoptosis; 2024 Oct; 29(9-10):1529-1545. PubMed ID: 38824477 [TBL] [Abstract][Full Text] [Related]
6. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway. Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877 [TBL] [Abstract][Full Text] [Related]
7. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma. Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304 [TBL] [Abstract][Full Text] [Related]
8. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation. Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711 [TBL] [Abstract][Full Text] [Related]
9. LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression. Wu R; Liu W; Yang Q; Zhang J; Hou P; Xiong J; Wu L; Li E Sci Rep; 2023 Oct; 13(1):16998. PubMed ID: 37813900 [TBL] [Abstract][Full Text] [Related]
10. SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma. Xie W; Shi L; Quan H; Xiao H; Chen J; Liu J; de Dieu Habimana J; Huang R; Luo J; Chen P; Li Z Cell Oncol (Dordr); 2023 Oct; 46(5):1285-1299. PubMed ID: 37099251 [TBL] [Abstract][Full Text] [Related]
11. N Yu F; Feng Y; Wang Q; Sun J Cell Biochem Biophys; 2024 Sep; 82(3):2321-2331. PubMed ID: 38872051 [TBL] [Abstract][Full Text] [Related]
12. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058 [TBL] [Abstract][Full Text] [Related]
13. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D. Wang Y; Cao K J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695 [TBL] [Abstract][Full Text] [Related]
14. SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. Chen Z; Yu M; Zhang B; Jin L; Yu Q; Liu S; Zhou B; Yan J; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Li H; Guo L Oncoimmunology; 2024; 13(1):2376264. PubMed ID: 38988824 [TBL] [Abstract][Full Text] [Related]
15. RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation. Han H; Shi Q; Zhang Y; Ding M; He X; Liu C; Zhao D; Wang Y; Du Y; Zhu Y; Yuan Y; Wang S; Guo H; Wang Q Oncogene; 2024 Oct; 43(41):3062-3077. PubMed ID: 39187545 [TBL] [Abstract][Full Text] [Related]
16. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model. Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma. Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302 [TBL] [Abstract][Full Text] [Related]
18. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma. Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366 [TBL] [Abstract][Full Text] [Related]
19. Protein O-fucosyltransferase 1 promotes PD-L1 stability to drive immune evasion and directs liver cancer to immunotherapy. Li Q; Guo W; Qian Y; Li S; Li L; Zhu Z; Wang F; Tong Y; Xia Q; Liu Y J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908854 [TBL] [Abstract][Full Text] [Related]
20. Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma. Huang CY; Wang Y; Luo GY; Han F; Li YQ; Zhou ZG; Xu GL J Immunother; 2017; 40(9):323-333. PubMed ID: 29028787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]